Clinical Trials Directory

Trials / Unknown

UnknownNCT03152175

Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators

Post-traumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators: A Cost-effectiveness and Efficacy Comparison of Treatment as Usual and a Novel Intervention

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
64 (estimated)
Sponsor
Douglas Mental Health University Institute · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Police officers, correctional service officers, and 911-operators are at increased risk for suffering from trauma-related disorders due to their direct and indirect exposure to life-threatening events, such as shootings, violent assaults, or car accidents, among others. Typical treatments for post-traumatic stress disorders include psychotherapy and pharmacological therapies (i.e., antidepressants). Although these interventions are effective for many sufferers, they all have limitations. Thus, the investigators propose to explore the usefulness of a new therapeutic technique, reconsolidation blockade, which involves reactivating the trauma memory while under the influence of propranolol. Objectives and hypotheses: To explore the efficacy and cost-effectiveness of reconsolidation blockade therapy as an adjunct treatment for trauma- and stressor-related disorders as defined in the Diagnostic and Statistical Manual Mental Disorders-5. The investigators hypothesize that, compared to the control group, 5 weekly trauma-memory reactivations under propranolol treatment will confer a significant reduction in trauma-related symptoms and significantly more health-related economic benefits. Stress symptoms and health-related costs will be assessed at 7, 26 and 52 weeks after study inclusion. In this study, the investigators will also explore the effects of reconsolidation blockade with propranolol on various neuropsychological functions.

Conditions

Interventions

TypeNameDescription
DRUGPropranolol Hydrochloride1mg / kg of propranolol hydrochloride, oral capsule
DRUGPlacebo1mg / kg of matched placebo, oral capsule

Timeline

Start date
2017-03-30
Primary completion
2022-03-01
Completion
2023-03-01
First posted
2017-05-12
Last updated
2021-06-18

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03152175. Inclusion in this directory is not an endorsement.